Menu Content

Key research

General

Control of PCV2 associated disease through vaccination

The review considers the problems that PCV2 has posed to vets trying to reduce associated mortality and morbidity in the pig herds under their care and the difference that the introduction of Ingelvac CircoFLEX® has made. The review also examines the results from the largest UK controlled trial.

Burch D. Control of PCV2 associated disease through vaccination. International Pig Topics 2008;23(8):13-15


PCVD Historical perspective and successful control

This symposium presents a broad overview of the historical impact of PCVD since its recognition in 1996, the benefits of piglet vaccination with Ingelvac CircoFLEX®, and the development of Ingelvac CircoFLEX®.

It demonstrates that the benefits of piglet vaccination are seen not only in severely affected herds, where it can significantly reduce mortality, but also in those herds where infection remains subclinical, where improved growth rate, better thrift and higher finishing weights provide a significant boost to profitability.

PCVD — Historical perspective and successful control. Boehringer Ingelheim Satellite Symposium, IPVS 2008, June 24, Durban


Seroprevalence of PCV2 in Canadian Swine Herds

Sera collected from 50 animals in 40 herds in the 5 major Canadian swine rearing provinces were analyzed for PCV2 antibodies (Abs).

100% of the herds were seropositive for PCV2. Overall, 83.2% of pigs in the 40 herds sampled tested positive for PCV2; 11.8 % tested negative, 5.4% were suspect. The rate of positives by age group were significantly less for end-of-nursery (8-10 weeks old) and early-finisher pigs (13 weeks old) than pigs in any other age group. This pinpoints a transition period between decaying passive maternal Abs and active seroconversion to PCV2 infection.

Cunningham GL, Desrosiers R, Sanford SE. Seroprevalence of PCV2 in Canadian Swine Herds. IPVS 2008


↑ Back to top